



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20521
WWW.USPTO.GOV

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/863,063	10/05/2001	1644	3472	09-2582 R-8		149	5

PHA 2011.2 (3167/72/US)

CONFIRMATION NO. 4628

FILING RECEIPT



OC000000006961753

Richard J Streit
Ladas & Parry
224 South Michigan Avenue Suite 1200
Chicago, IL 60604

Date Mailed: 10/25/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

John P. McKeam, Glencoe, MO;
Gary Gordon, Highland, IL;
James J. Cunningham, Chicago, IL;
Stephen T. Gately, Palatine, IL;
Alane T. Koki, Beaufort, MO;
Jaime L. Masferrer, Ballwin, MO;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/30776 12/22/1999
AND CLAIMS BENEFIT OF 60/113,786 12/23/1998

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

METHOD OF

~~Method~~ of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia

Preliminary Class

530

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

*Title
needs
time*

JC
JCWSCS 3 0 DEC 2003

DT20 Rec'd PCT/PTO 29 DEC 2003 CT

DEC-29-2003 MON 02:56 PM SENNIGER POWERS LEAVITT

FAX NO. 3145881357

P. 01

Law Offices of
SENNIGER, POWERS, LEAVITT AND ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
Telephone (314) 231-5400
Facsimile (314) 231-4342

FACSIMILE TRANSMITTAL COVER SHEET

DATE: December 29, 2003 ATTORNEY DOCKET #: 3167/7Z/US (PHA 2011.2)

PTO FACSIMILE NUMBER: (703) 746-9195

PLEASE DELIVER THIS FACSIMILE TO:

Office of Initial Patent Examination's Filing Receipt Corrections

THIS FACSIMILE IS BEING SENT BY: Kathryn J. Doty, Esq.

NUMBER OF PAGES: 5 INCLUDING COVER SHEET

TIME SENT: 2:55 pm OPERATOR'S NAME M. Susan Clements
(CDT)

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that these papers are being transmitted via facsimile to the Commissioner for Patents on the date shown below.

M. Susan Clements

Typed or printed name of person signing certification

M. Susan Clements

Signature

December 29, 2003

Date

Type of papers transmitted: Request for Corrected Filing Receipt

Applicant's Name: John P. McKearn, et al.

Serial No. (Control No.): 09/868,063 Examiner: J.D. Goldberg

Filing Date: October 5, 2001 Art Unit: 1644

Application Title: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND A MATRIX METALLOPROTEINASE INHIBITOR AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA

IF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS POSSIBLE. CONFIRMING NUMBER IS (314) 231-5400.

Senniger, Powers, Leavitt & Roedel

Attorneys at Law

Patents, Trademarks, Copyrights,
Technology Law, Antitrust, LitigationOne Metropolitan Square, 16th Floor
Saint Louis, Missouri 63102Telephone: 314-231-5400
Facsimile: 314-231-4342

www.senniger.com

Kathryn J. Doty
kdoty@senniger.com

December 29, 2003

Application of John P. McKearn et al.

Art Unit 1644

Serial No. 09/868,063

Filed October 5, 2001

Confirmation No. 4628

For METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND A MATRIX
METALLOPROTEINASE INHIBITOR AS A COMBINATION THERAPY IN THE
TREATMENT OF NEOPLASIA

Examiner J.D. Goldberg

Attorney Docket 3167/7Z/US (PHA 2011.2); formerly CU-2562RJS

Office of Initial Patent Examination's

Customer Service Center

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450


Sir:

We have received the filing receipt in the above-referenced U.S. patent application.

The receipt shows the Title as "Methof of using a Cyclooxygenase-2 Inhibitor and a Matrix Metalloproteinase Inhibitor as a Combination Therapy in the Treatment of Neoplasia" whereas the correct information is "**Method of** of using a Cyclooxygenase-2 Inhibitor and a Matrix Metalloproteinase Inhibitor as a Combination Therapy in the Treatment of Neoplasia". In addition, please change the Attorney Docket No. from CU-2562 RJS to **PHA 2011.2 (3167/7Z/US)**.

* A copy of the Filing Receipt with the changes noted thereon is enclosed as well as a copy of an executed Power of Attorney. Please send us a corrected filing receipt.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593

KJD/msc

*Enclosure